RVMD

$202.00-$3.26 (-1.59%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$44.0B

214M shares

52-week range

$35.22 – $208.76

96% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Change+$176.39

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$136M	+3814.8%	$-8.99	$-9.71–$-8.17	—	17
2027	$961M	+604.2%	$-6.37	$-14.08–$1.26	—	15
2028	$2.1B	+114.5%	$-2.02	$-7.51–$7.92	—	15
2029	$4.0B	+94.1%	$4.55	$1.68–$13.56	44.4×	9

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 0 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-05	$-2.04	$-3.06	-50.0%
2026-05-06	$-1.84	$-2.29	-24.5%
2026-02-25	$-1.58	$-1.86	-17.7%
2025-11-05	$-1.42	$-1.61	-13.4%
2025-08-06	$-0.94	$-1.31	-39.4%
2025-05-07	$-1.12	$-1.13	-0.9%
2025-02-26	$-1.01	$-1.12	-10.9%
2024-11-06	$-0.89

DCF fair valuemodel estimate

Intrinsic value

$0.88

Price

$202.00

Implied downside

-100%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
RVMDRevolution Medicines, Inc.	$202.00	-1.59%	$42.9B	—
ASNDAscendis Pharma A/S	$246.23	-3.61%	$15.3B	—
BBIOBridgeBio Pharma, Inc.	$81.21	-3.14%	$15.9B	—
BMRNBioMarin Pharmaceutical Inc.	$68.53	-2.43%	$13.2B	—
EXELExelixis, Inc.	$50.61	+0.46%

Revolution Medicines, Inc. Common Stock

Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

www.revmed.com

Employees: 883
IPO / List date: Feb 13, 2020
HQ: REDWOOD CITY, CA

Held by traders on TradeandTell

No one on the platform currently holds RVMD.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	6,200	$603.0K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded RVMD yet.

$RVMD chatter on StockTwits

Tony M@SellasgpsCurativeBAT11Bullish16h
$ABVX $CDTX $RVMD $SLS Why am I sharing this with my fellow Sellas Brothers and Sisters? Because shorts try to create a doubt in your heads and “Doubt kills more dreams everyday than failure ever will” Hold with Conviction and stay strong 💪 ✌️🙏❤️‍🩹
View on StockTwits ↗
Tony M@SellasgpsCurativeBAT11Bullish16h
$ABVX $CDTX $RVMD $SLS A picture is worth a thousand words $CDTX was my biggest hit of all time. I started buying $CDTX a little over $2.13 after watching the ticker passing by on CNBC a few years ago.👇 Merck completed its acquisition of Cidara Therapeutics (NASDAQ: CDTX) on January 7, 2026, buying the biotechnology company for $221.50 per share in cash. The total transaction value was approximately $9.2 billion. Hold with Conviction because opportunities like this come very rarely. Don’t step over a hundred dollar 💵 Bills to pick up Pennie’s.👇 ✌️🙏❤️‍🩹
View on StockTwits ↗
Mr fud@Mrfudd19h
$ARDX you could have sold this in the $5s late winter/spring of last year and bought the best in biotech at rock bottom prices like $RVMD instead youre bag holding forever
View on StockTwits ↗
Dakota Quint@villagestoreBearish1d
$SLS bulls think this wt1 immunotherapy is like $RVMD ras inhibitor. Couldnt be further apart. The time to unblinding the regal trial has put bulls on a 1 way thought loop thats going to gut them.
View on StockTwits ↗
Roman@Universaal1d
$RVMD what a trash overblown
View on StockTwits ↗
$$JJDollar$$@JJkash1d
$IONQ, $NBIS , $RVMD By 2030 i will be pooping in a Gold toilet and giving half my money to St Judes childrens hospital
View on StockTwits ↗
Dude Manguy@ColoradicalBullish1d
@EmSol hell yeah, you $RVMD longs must have fat stacks of cash! This is a very real, very imminent clinical portfolio over here at $SLS that is about to change the oncology landscape. The fact we are still waiting on the 80th GPS trial patient death already means an HR below .5. Our second asset, a very promising CDK9 inhibitor is already worth 2x the SP. we just need VOLUME to stick it to our horrible MM. GLTA
View on StockTwits ↗
Emsol@EmSol1d
$RVMD $SLS I was block after this post, that’s rude
View on StockTwits ↗
Emsol@EmSolBullish1d
$RVMD $SLS follow me Revmed friend, take some profit and let try to see what happen with SLS for the patient sake
View on StockTwits ↗
Emsol@EmSol1d
$RVMD $SLS good luck, I hope you will get the success we had with Revmed. Wishing you the best my friend, for your portofolio and for all patients, my only point is until result, not sure and will wait , I may buy a lottery ticket with 3000 shares and see..
View on StockTwits ↗
Emsol@EmSol1d
$RVMD $SLS long way to go… maybe it will be a buy if they don’t fail trial but for now, stay with the winning side
View on StockTwits ↗
5,500% ROI this quarter@55X_ROI_Q1_20261d
$RVMD $SLS @EmSol are Stupid or Dumb? SLS is about to announce Phase 3 Registrational Trial Results 6 years in the making that will give Gps - a revolutionary AML remission maintenance immunotherapy, the fda green light to Generate 10's of billions of Dollars .. . . real revenue that is wort 25x the current market rigged mcap. @Geukinas what? SLS has $140M in CASH / a tiny $9M quarterly burn... Plus NO PLANS To commercialize, since you're a bit new, the Ceo disclosed they are in discussions for partnership and beyond and would 'announce publicly when they have something concrete" -- a direct quote from the asm.
View on StockTwits ↗
Achouffe@AchouffeBullish1d
$RVMD $SLS But $SLS has the biggest potential from this point onward. Don’t look at the past, live for today 😉
View on StockTwits ↗
Emsol@EmSol1d
$RVMD $SLS stop to compare Apple and banana or gold and shit.. SLS are 5 years behind Revmed, no solid data to present and burn cash
View on StockTwits ↗
Tony M@SellasgpsCurativeBAT11Bullish1d
$RVMD $SLS Part 6. 🤩 👇✌️🙏❤️‍🩹
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.